PKK Library

Your cart is empty.

Welcome to P K Kelkar Library, Online Public Access Catalogue (OPAC)

Optimizing the “Drug-Like” Properties of Leads in Drug Discovery (Record no. 502251)

000 -LEADER
fixed length control field 04585nam a22004815i 4500
001 - CONTROL NUMBER
control field 978-0-387-44961-6
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20161121230654.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 100301s2006 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780387449616
-- 978-0-387-44961-6
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-0-387-44961-6
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM1-950
072 #7 - SUBJECT CATEGORY CODE
Subject category code MMG
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED071000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615
Edition number 23
245 10 - TITLE STATEMENT
Title Optimizing the “Drug-Like” Properties of Leads in Drug Discovery
Medium [electronic resource] /
Statement of responsibility, etc. edited by Ronald T. Borchardt, Edward H. Kerns, Michael J. Hageman, Dhiren R. Thakker, James L. Stevens.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York, NY :
Name of producer, publisher, distributor, manufacturer Springer New York,
Date of production, publication, distribution, manufacture, or copyright notice 2006.
300 ## - PHYSICAL DESCRIPTION
Extent X, 512 p. 190 illus., 39 illus. in color.
Other physical details online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type text file
Encoding format PDF
Source rda
490 1# - SERIES STATEMENT
Series statement Biotechnology: Pharmaceutical Aspects ;
Volume/sequential designation IV
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Strategic Use of Preclinical Pharmacokinetic Studies and In Vitro Models in Optimizing ADME Properties of Lead Compounds -- Role of Mechanistic Transport Studies in Lead Optimization -- Metabolic Activation-Role in Toxicity and Idiosyncratic Reactions -- Case History — Use of ADME Studies for Optimization of Drug Candidates -- Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization -- Lipid-based Systems, Drug Exposure and Lead Optimization -- Biopharmaceutics Modeling and the Role of Dose and Formulation on Oral Exposure -- Application of Physicochemical Data to Support Lead Optimization by Discovery Teams -- Computational Models Supporting Lead Optimization in Drug Discovery -- Prodrug Strategies for Improving Drug-Like Properties -- The Application of Multivariate Data Analysis to Compound Property Optimization -- Case History: Toxicology Biomarker Development Using Toxicogenomics -- Predicting Idiosyncratic Drug Reactions -- Elementary Predictive Toxicology for Advanced Applications -- The Application of PK/PD Modeling and Simulations During Lead Optimization -- Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization -- Optimizing Biomarker Development for Clinical Studies at the Lead Optimization Stage of Drug Development -- The Relevance of Transporters in Determining Drug Disposition.
520 ## - SUMMARY, ETC.
Summary, etc. Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, “drug-like” properties refer to the molecule’s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmacology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmacology/Toxicology.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Borchardt, Ronald T.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Kerns, Edward H.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Hageman, Michael J.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Thakker, Dhiren R.
Relator term editor.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Stevens, James L.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Printed edition:
International Standard Book Number 9780387340562
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Biotechnology: Pharmaceutical Aspects ;
Volume/sequential designation IV
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-0-387-44961-6
912 ## -
-- ZDB-2-SBL
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Barcode Date last seen Price effective from Koha item type
        PK Kelkar Library, IIT Kanpur PK Kelkar Library, IIT Kanpur 2016-11-21 EBK2538 2016-11-21 2016-11-21 E books

Powered by Koha